Cairo Pharmaceuticals results, Q3 2026
Net profit, assets, equity and cash flow for Q3 2026, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit144 millionEGP · −67.6% vs the same period a year earlier
Shareholders' equity1.16 billionEGP · +11.0% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Q3 2026 was about 144 million EGP, down −67.6% from 444 million EGP in Q3 2025.
Key lines against the same period a year earlier
This periodQ3 2025Change
Net profit144 million444 million−67.6%
Gross profit197 million823 million−76.0%
Total assets—2.03 billion—
Total liabilities—980 million—
Shareholders' equity1.16 billion1.05 billion+11.0%
Total liabilities and equity2.33 billion2.03 billion+14.9%
Operating cash flow—379 million—
Investing cash flow—-118 million—
Financing cash flow—-257 million—
Net change in cash—2.93 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy